M
Morphic Therapeutic
Biotechnology company developing a new generation of oral integrin therapies
About Morphic Therapeutic
Morphic Therapeutic is at the forefront of developing a new generation of oral integrin drugs, leveraging decades of expertise and a unique integrin discovery platform. The company aims to revolutionize the treatment landscape for patients suffering from serious chronic diseases such as autoimmune disorders, cardiovascular conditions, metabolic diseases, fibrosis, and cancer.
Morphic operates in the biopharmaceutical industry, targeting a specialized market of patients with chronic and severe health conditions. The company's business model revolves around the research, development, and commercialization of oral integrin drugs. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved drugs.
Morphic's integrin platform is supported by significant partnerships with major healthcare investors and organizations, which provide both financial backing and strategic guidance. The company is led by a team of experienced scientists and industry leaders, including founder Timothy Springer, PhD, and Chief Scientific Officer Shelia Violette, PhD.
The company’s innovative approach focuses on making integrin-targeting therapies more accessible and effective by developing oral formulations, which could offer a more convenient alternative to current treatments that often require injections or infusions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2015
- Headquarters
- Waltham, United States
- Listing
- IPO 2019
- Employees
- 31
- Open positions
- None listed
- Dealroom signal
- 26.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2024 | $3.2B | $3.2B | Eli Lilly | ↗ |
| POST IPO EQUITYOther financing | Mar 2023 | $100M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $330K | 0% | −$178M | -53816.7% |
| 2025 | $330K | +32% | −$178M | -53816.7% |
| 2024 | $250K | -52% | −$178M | -71038% |
| 2023 | $521K | -99.3% | −$178M | -34087.3% |
| 2022 | $71M | +257.7% | −$63M | -89.5% |
| 2021 | $20M | -56% | −$96M | -484% |
| 2020 | $45M | — | −$47M | -105% |
Growth signals
Latest recorded traffic for Morphic Therapeutic is 400 monthly website visits, down 91.5% over the last three months. Morphic Therapeutic's team declined 77.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
SR One
ShangPharma
Abbvie Biotech Ventures
Polaris Partners
Schrodinger
Omega Funds
Timothy A. Springer
Novo Seeds
Invus
Novo Holdings
EcoR1 Capital
Other known investors2 additional known investors
Eli Lilly
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Morphic Therapeutic on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Morphic Therapeutic’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.